When was Alligator Bioscience founded?

Alligator Bioscience was founded in 2001 and raised its 1st funding round 14 years after it was founded.

Where is Alligator Bioscience located?

Alligator Bioscience is headquartered in Lund, Sweden.

How many employees does Alligator Bioscience have?

As of Apr 30, 2026, the latest employee count at Alligator Bioscience is 28.

Is Alligator Bioscience a funded company?

Alligator Bioscience is a funded company, having raised a total of $10M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 01, 2015.

When was the latest funding round of Alligator Bioscience?

Alligator Bioscience's latest funding was a $***** Grant (prize money) round on Oct 05, 2018, with participation from 1 investor.

Where does Alligator Bioscience rank among its competitors?

Alligator Bioscience ranks 356th amongst 3261 active competitors, of which 1125 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Alligator Bioscience?

Alligator Bioscience's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Alligator Bioscience - 2026 Company Profile, Funding & Competitors

Alligator Bioscience is a public company based in Lund (Sweden), founded in 2001. It operates as a Developer of antibody-based immunotherapies for the treatment of cancer. Alligator Bioscience has raised $10M in funding. The company has 3261 active competitors, including 1125 funded and 770 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of antibody-based immunotherapies for the treatment of cancer. The proprietary technology platforms include the human antibody library ALLIGATOR-GOLD and the protein optimization technology FIND. The pipeline consists of ADC-1013 a CD40 agonistic human monoclonal antibody, ADC-1015 is a bispecific antibody directed towards OX40 and CTLA-4 and ADC-1016 is a bispecific immuno-oncology.

Website: alligatorbioscience.se/en/
Social

Key Metrics

Founded Year

2001

Location

Lund, Sweden

Stage

Public

Total Funding

$10M in 2 rounds

Latest Funding Round

Grant (prize money), Oct 05, 2018, $*****

Investors

Sunstone & 9 more

Ranked

356^th among 3261 active competitors

Employee Count

28 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3034 more

Exit Details

Public

View Alligator Bioscience's full profile

Alligator Bioscience got listed on Nov 23, 2016.

Click here to take a look at Alligator Bioscience's IPO in detail

Alligator Bioscience has raised a total funding of $10M over 2 rounds. Its first funding round was on Oct 01, 2015. Its latest funding round was a Grant (prize money) round on Oct 05, 2018 for $*****. 1 investor participated in its latest round. Alligator Bioscience has 10 institutional investors.

Here is the list of recent funding rounds of Alligator Bioscience:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 05, 2018	1450995	Grant (prize money)	3412975	7494954	9576011	4228147
Oct 01, 2015	8858697	Series A	5582511	3688626	4927887	1241325

Access funding benchmarks and valuations. Sign up today!

View details of Alligator Bioscience's funding rounds and investors

Alligator Bioscience's employee count trend

Alligator Bioscience has 28 employees as of Apr 26. Here is Alligator Bioscience's employee count trend over the years:

Employee count trend for Alligator Bioscience

Uncover Alligator Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alligator Bioscience include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Alligator Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
356th	Alligator Bioscience 2001, Lund (Sweden), Public	Developer of antibody-based immunotherapies for the treatment of cancer	$10M	Sunstone, Allegro Investment Fund & 8 others	56/100